Literature DB >> 35567651

Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection.

Leila Rezaie Shirmard1, Mohammad Shabani2, Amin Ashena Moghadam2, Nasim Zamani2, Hadi Ghanbari2, Ahmad Salimi3,4.   

Abstract

Mitochondrial dysfunction may lead to cardiomyocyte death in trastuzumab (TZM)-induced cardiotoxicity. Accordingly, this study was designed to evaluate the mitochondrial protective effects of curcumin, chrysin and thymoquinone alone in TZM-induced cardiotoxicity in the rats. Forty-eight male adult Wistar rats were divided into eight groups: control group (normal saline), TZM group (2.5 mg/kg I.P. injection, daily), TZM + curcumin group (10 mg/kg, I.P. injection, daily), TZM + chrysin (10 mg/kg, I.P. injection, daily), TZM + thymoquinone (0.5 mg/kg, I.P. injection, daily), curcumin group (10 mg/kg, I.P. injection, daily), chrysin group (10 mg/kg, I.P. injection, daily) and thymoquinone group (10 mg/kg, I.P. injection, daily). Blood and tissue were collected on day 11 and used for assessment of creatine phosphokinase, lactate dehydrogenase (LDH), troponin, malondialdehyde (MDA) amount, glutathione levels and mitochondrial toxicity parameters. TZM increased mitochondrial impairments (reactive oxygen species formation, mitochondrial swelling, mitochondrial membrane potential collapse and decline in succinate dehydrogenase activity) and histopathological alterations (hypertrophy, enlarged cell, disarrangement, myocytes degeneration, infiltration of fat in some areas, hemorrhage and focal vascular thrombosis) in rat heart. As well as TZM produced a significant increase in the level of CK, LDH, troponin, MDA, glutathione disulfide. In most experiments, the co-injection of curcumin, chrysin and thymoquinone with TZM restored the level of CK, LDH, troponin, MDA, GSH, mitochondrial impairments and histopathological alterations. The study revealed the cardioprotective effects of curcumin, chrysin and thymoquinone against TZM-induced cardiotoxicity which could be attributed to their antioxidant and mitochondrial protection activities.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anticancer drugs; Antioxidant; Cardiac mitochondria; Cardioprotective; Mitoprotective

Mesh:

Substances:

Year:  2022        PMID: 35567651     DOI: 10.1007/s12012-022-09750-w

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  40 in total

1.  Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Authors:  Nishant Mohan; Jiangsong Jiang; Milos Dokmanovic; Wen Jin Wu
Journal:  Antib Ther       Date:  2018-08-31

Review 2.  Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases.

Authors:  Opher S Kornfeld; Sunhee Hwang; Marie-Hélène Disatnik; Che-Hong Chen; Nir Qvit; Daria Mochly-Rosen
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

3.  Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.

Authors:  Tiina Moilanen; Anna Jokimäki; Olli Tenhunen; Jussi P Koivunen
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-05       Impact factor: 4.553

Review 4.  Neuregulin-1/ErbB signaling and chronic heart failure.

Authors:  Yabei Xu; Xinyan Li; Xifu Liu; Mingdong Zhou
Journal:  Adv Pharmacol       Date:  2010

Review 5.  Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy.

Authors:  Mohanad Gabani; Diana Castañeda; Quynh My Nguyen; Soo-Kyoung Choi; Cheng Chen; Ayesha Mapara; Adam Kassan; Alexis A Gonzalez; Tahsin Khataei; Karima Ait-Aissa; Modar Kassan
Journal:  Cureus       Date:  2021-09-22

Review 6.  Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Neil L Spector; Kimberly L Blackwell
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.

Authors:  Somaira Nowsheen; Paul V Viscuse; Ciara C O'Sullivan; Nicole P Sandhu; Tufia C Haddad; Anne Blaes; Jennifer Klemp; Lara Nhola; Joerg Herrmann; Kathryn J Ruddy
Journal:  Curr Breast Cancer Rep       Date:  2017-07-14

8.  Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Authors:  Yong Ji; Jian Lv; Di Sun; Yufeng Huang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

Review 9.  A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.

Authors:  Mohammed I El-Gamal; Nada H Mewafi; Nada E Abdelmotteleb; Minnatullah A Emara; Hamadeh Tarazi; Rawan M Sbenati; Moustafa M Madkour; Seyed-Omar Zaraei; Afnan I Shahin; Hanan S Anbar
Journal:  Molecules       Date:  2021-12-05       Impact factor: 4.411

10.  Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.

Authors:  Somaira Nowsheen; Khaled Aziz; Jae Yoon Park; Amir Lerman; Hector R Villarraga; Kathryn Jean Ruddy; Joerg Herrmann
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.